Clinical Trial Update: Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial investigating imiquimod to detect residual lesions and prevent recurrence of lentigo maligna.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lentigo Maligna

Drugs mentioned

• Imiquimod (imiquimod)

Snippet

Sponsor: Medical University of Graz | Conditions: Lentigo Maligna | Phase 2, Phase 3 | Status: UNKNOWN